Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Veru Inc VERU

Consumer Defensive Household & Personal Products
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed in two different programs... see more

Recent & Breaking News (NDAQ:VERU)

Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023

GlobeNewswire September 20, 2023

Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer

GlobeNewswire September 11, 2023

Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023

GlobeNewswire August 30, 2023

Veru Reports Fiscal 2023 Third Quarter Financial Results

GlobeNewswire August 10, 2023

Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023

GlobeNewswire August 3, 2023

Veru Inc.'s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants

GlobeNewswire June 21, 2023

Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board

GlobeNewswire June 1, 2023

Veru to Present at the Jefferies Healthcare Conference

GlobeNewswire May 24, 2023

Veru Reports Fiscal 2023 Second Quarter Financial Results

GlobeNewswire May 11, 2023

Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS

GlobeNewswire May 4, 2023

Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital

GlobeNewswire May 3, 2023

Veru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023

GlobeNewswire April 27, 2023

Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones

GlobeNewswire April 20, 2023

Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector

GlobeNewswire April 19, 2023

Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses

GlobeNewswire April 11, 2023

Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program

GlobeNewswire April 4, 2023

Veru to Present at the Oppenheimer 33rd Annual Healthcare Conference

GlobeNewswire March 7, 2023

Veru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for ARDS

GlobeNewswire March 2, 2023

Veru Reports Fiscal 2023 First Quarter Financial Results

GlobeNewswire February 9, 2023

Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Veru Inc. (VERU) Investors of Class Action and to Actively Participate

Business Wire February 6, 2023